NCT07172958View on ClinicalTrials.gov

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 22, 2025

Primary Completion Date

December 31, 2035

Study Completion Date

December 31, 2038

Conditions
RhabdomyosarcomaEwing SarcomaNeuroblastomaWilms Tumor
Interventions
BIOLOGICAL

Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells

Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells

Trial Locations (1)

20010

Childrens National Hospital, Washington D.C.

Sponsors

Collaborators (1)

Cancer Research UK
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Cancer Research UK

OTHER

collaborator

The Mark Foundation for Cancer Research

UNKNOWN

lead

Children's National Research Institute

OTHER